Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 292 Urinary Bladder Neoplasms 39 Neoplasm Metastasis 35 Carcinoma, Non-Small-Cell Lung 24 Carcinoma, Transitional Cell 23 Neoplasms 21 Breast Neoplasms 20 Lung Neoplasms 13 Carcinoma, Renal Cell 13 Ovarian Neoplasms 12 Stomach Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 11 Non-Muscle Invasive Bladder Neoplasms 10 Melanoma 9 Small Cell Lung Carcinoma 7 Salivary Gland Neoplasms 7 Prostatic Neoplasms, Castration-Resistant 7 Head and Neck Neoplasms 7 Esthesioneuroblastoma, Olfactory 7 Esophageal Neoplasms 7 Colorectal Neoplasms 7 Urethral Neoplasms 6 Uterine Cervical Neoplasms 5 Triple Negative Breast Neoplasms 5 Prostate Cancer Metastatic 5 Pancreatic Neoplasms 5 Metastatic Castration-resistant Prostate Cancer 5 Kidney Neoplasms 5 Adenocarcinoma 5 Sarcoma 4

Interventions

tislelizumab 1 pamiparib 1 TNFeraseBiologic 1 Injections 1 Gefitinib 1 Docetaxel 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Locally Advanced Prostate Cancer × Docetaxel × Genitourinary × Clear all

NCT06387056 2024-04-26

SEGNO

The First Affiliated Hospital of Xiamen University

Phase 2 Recruiting

Locally Advanced Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡